Faculty, Staff and Student Publications

Publication Date

9-1-2023

Journal

Leukemia & Lymphoma

Abstract

Increased rates of clinically significant bleeding have been reported with ibrutinib, however, limited data is available on the risk when given with concomitant therapeutic anticoagulation. We analyzed the incidence of major bleeding in 64 patient exposures that received ibrutinib with concomitant therapeutic anticoagulation. Major bleeding was observed in 5/64 (8%) patient exposures. The highest incidence was observed with rivaroxaban (3/17, 18%), followed by apixaban (2/35, 6%). No major bleeding events were seen with enoxaparin (n = 10). A total of 38% of patient exposures received a concomitant antiplatelet agent along with therapeutic anticoagulation. Among these patients, one (4%) experienced a fatal hemorrhage while taking ibrutinib, apixaban, and clopidogrel concomitantly. Our retrospective study observed a higher rate of major hemorrhage with combined DOAC with ibrutinib than historically reported with ibrutinib alone. This combination may be associated with increased risk of major bleeding and further prospective studies evaluating this risk are necessary.

Keywords

Humans, Anticoagulants, Leukemia, Lymphocytic, Chronic, B-Cell, Incidence, Prospective Studies, Retrospective Studies, Hemorrhage, chronic lymphocytic leukemia, ibrutinib, anticoagulation, major bleeding, direct oral anticoagulant, enoxaparin

DOI

10.1080/10428194.2023.2223740

PMID

37317991

PMCID

PMC11874373

PubMedCentral® Posted Date

3-3-2025

PubMedCentral® Full Text Version

Author MSS

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.